- Home
- MIRA vs AADI Comparison
MIRA vs AADI Comparison
Compare MIRA & AADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- AADI
- Stock Information
- Founded
- MIRA 2020
- AADI 2011
- Country
- MIRA United States
- AADI United States
- Employees
- MIRA N/A
- AADI N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- AADI Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- AADI Health Care
- Exchange
- MIRA Nasdaq
- AADI Nasdaq
- Market Cap
- MIRA 17.1M
- AADI 49.5M
- IPO Year
- MIRA 2023
- AADI N/A
- Fundamental
- Price
- MIRA $2.04
- AADI $1.99
- Analyst Decision
- MIRA Strong Buy
- AADI Hold
- Analyst Count
- MIRA 2
- AADI 3
- Target Price
- MIRA $14.00
- AADI $1.75
- AVG Volume (30 Days)
- MIRA 2.1M
- AADI 86.8K
- Earning Date
- MIRA 11-11-2024
- AADI 11-06-2024
- Dividend Yield
- MIRA N/A
- AADI N/A
- EPS Growth
- MIRA N/A
- AADI N/A
- EPS
- MIRA N/A
- AADI N/A
- Revenue
- MIRA N/A
- AADI $23,817,000.00
- Revenue This Year
- MIRA N/A
- AADI $4.79
- Revenue Next Year
- MIRA N/A
- AADI $10.72
- P/E Ratio
- MIRA N/A
- AADI N/A
- Revenue Growth
- MIRA N/A
- AADI 10.57
- 52 Week Low
- MIRA $0.51
- AADI $1.21
- 52 Week High
- MIRA $6.40
- AADI $5.70
- Technical
- Relative Strength Index (RSI)
- MIRA 79.14
- AADI 50.61
- Support Level
- MIRA $1.05
- AADI $1.97
- Resistance Level
- MIRA $1.99
- AADI $2.06
- Average True Range (ATR)
- MIRA 0.15
- AADI 0.09
- MACD
- MIRA 0.11
- AADI -0.02
- Stochastic Oscillator
- MIRA 95.38
- AADI 29.82
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.